Ann: Security Class Reinstatement to Quotation- OPTOB, page-657

I don’t think control arm over performance is a safety issue but purely efficacy so the trial will continue regardless. My point is that control arms/monotherapy/standard of care at 52w is well known given these drugs have been on the market for 20+ years so therefore logically any overperformance is due to combo arms.

as before below - the line is fairly flat after 24w